FFN511 - ≥98% , CAS No.1004548-96-2

CAS: 1004548-96-2 Cat. No.: F274714 Molecular Weight: 284.35

GRADE & PURITY ≥98%

Synonyms

9-(2-aminoethyl)-2,3,6,7-tetrahydro-1H-pyrano[2,3-f]pyrido[3,2,1-ij]quinolin-11(5H)-one

Storage

Store at -20°C,Desiccated

Shipped In

Ice chest + Ice pads

Overview

FFN511 is a potent fluorescent false neurotransmitters (FFNs) that targets neuronal vesicular monoamine transporter 2 (VMA T2). FFN511 inhibits serotonin binding to VMA T2-containing membranes with an IC50 of 1 µM. FFN511 directly images the dynamics of release during exocytosis, can be used to label dopamine terminals in live cortical-striatalacute slices。

Specifications

Synonyms

9-(2-aminoethyl)-2, 3, 6, 7-tetrahydro-1H-pyrano[2, 3-f]pyrido[3, 2, 1-ij]quinolin-11(5H)-one

Specifications & Purity

≥98%

Biochemical and Physiological Mechanisms

First novel fluorescent false neurotransmitter. Enables optical imaging of presynaptic terminal activity. Inhibits 5-HT binding to VMAT2 (IC 50 = 1 µM (comparable to dopamine itself)). Released via exocytosis in the striatum in mouse acute slice preparati

Storage

Store at -20°C, Desiccated

Shipped In

Ice chest + Ice pads

This product requires cold chain shipping. Ground and other economy services are not available.

Action Type

INHIBITOR

Note

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. To make a 10 μM solution for slice incubation, 25 μl of a 20 mM FFN511 stock solution in DMSO is added to 50 ml of ACSF. This results in a 10 μM FFN511 solution in ACSF containing 0.05% DMSO. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

Purity

≥98%

Names and Identifiers

• Canonical Smiles: C1CC2=CC3=C(C4=C2N(C1)CCC4)OC(=O)C=C3CCN.C(=O)(C(F)(F)F)O
• IUPAC Name: 6-(2-aminoethyl)-3-oxa-13-azatetracyclo[7.7.1.02,7.013,17]heptadeca-1(17),2(7),5,8-tetraen-4-one;2,2,2-trifluoroacetic acid
• InChIKey: XHUSAIWAUAMZRG-UHFFFAOYSA-N
• INCHI: 1S/C17H20N2O2.C2HF3O2/c18-6-5-11-10-15(20)21-17-13-4-2-8-19-7-1-3-12(16(13)19)9-14(11)17;3-2(4,5)1(6)7/h9-10H,1-8,18H2;(H,6,7)
• Isomeric SMILES: C1CC2=CC3=C(C4=C2N(C1)CCC4)OC(=O)C=C3CCN.C(=O)(C(F)(F)F)O
• Molecular Weight: 284.35
• Reaxy-Rn: 23051490
• Reaxys-RN_link_address: https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=23051490&ln=

Chemical and Physical Properties

• Solubility: Soluble in DMSO to 100 mM and in ethanol to 100 mM

References

1. Chen Zhou, Feifei Wu, Liqing He, Huijie Yan, Zhaowei Zhang, Shuang Zhao, Wenyi Huang, Yuhao Luo, Wei Zhao, Bulong Gao, Zherui Zhang, Yaofeng Zhou, Baiheng Wu, Junqiu Liu, Dingcheng Zhu.  (2025)  An Implant-Free Nanosystem Enabling Synergistic Oxidative Damage Mitigation and Deep Brain Stimulation for Alleviating Parkinsonian Symptoms.  ACS Nano,      [PMID:40664603] [10.1021/acsnano.5c06227]